ICARE Social Media Post January 2020

Advances in Treatment for Lynch Syndrome-Related Endometrial Cancer

A recent phase II study showed increased response to an immunotherapy drug (avelumab), in women with endometrial cancer with mismatch repair deficiency.

Among women with Lynch Syndrome, the risk for endometrial cancer (which often has mismatch repair deficiency) is raised. This new study shows promising treatment options for women with endometrial cancer and Lynch syndrome with recurrent or persistent endometrial cancer.

Check out the full article at the Journal of Clinical Oncology: https://lnkd.in/embydpk

Permanent link to this article: https://inheritedcancer.net/13020/